_20240503205303original_image_4.webp)
In a significant breakthrough in reproductive medicine, Jindal IVF, an institute specialising in Assisted Reproductive Technology (ART) and In Vitro Fertilisation (IVF), celebrates a landmark achievement with the successful completion of a Preimplantation Genetic Testing for Human Leukocyte Antigen (PGT-HLA) case. This groundbreaking procedure offers hope and a potential cure for families grappling with genetic challenges, particularly thalassemia major.
The journey of this case commenced in January 2019 when a couple, whose first child was diagnosed with thalassemia major, sought assistance from Jindal IVF. Under the guidance of Dr Sheetal Jindal, Senior Consultant and IVF-PGT expert, alongside Geneticist Dr Sangeeta Khattar, the medical team devised a tailored treatment plan to address the couple’s unique needs. The objective was to conceive a healthy sibling who could serve as a bone marrow donor for their ailing child.
“From the outset, we understood the significance of this endeavour,” states Dr. Sheetal Jindal. “Our aim was not only to fulfill the family’s aspirations but also to offer hope to countless others facing similar genetic dilemmas. The challenges were immense, but our determination to succeed never wavered.”
The complex treatment protocol involved multiple IVF cycles and rigorous genetic screening procedures. Over several months, the couple underwent three IVF cycles, each demanding intensive hormonal stimulation and meticulous care. Despite the inherent uncertainties, the perseverance of both the medical team and the hopeful couple eventually paid off.
After the third IVF cycle, the couple received the long-awaited news: a healthy embryo, free from thalassemia and with HLA matching. The successful implantation of this embryo culminated in the birth of a healthy baby on 4th April 2024, heralding a new era of hope and joy for the family.
“We take immense pride in this achievement,” affirms Dr. Sheetal Jindal. “It underscores the transformative potential of reproductive medicine in overcoming genetic challenges and shaping lives. I extend my heartfelt gratitude to the dedicated team at Jindal IVF for their unwavering commitment and pursuit of excellence.”
The patient, whose identity remains confidential, expresses profound gratitude to the entire team at Jindal IVF for their expertise and compassion, which resulted in the birth of a healthy baby and renewed hope for the future.
Jindal IVF continues to monitor the health of the newborn and plans to conduct HLA Matching tests after 6 months to 1 year to ensure a fully matched report. Meanwhile, preparations are underway for a bone marrow transplant for the elder sibling affected by thalassemia major, scheduled to take place after 2 years.
